Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: Observations from the ESPRIT trial

Journal of the American College of Cardiology

Volumn 41, Issue 3, 2003, Pages 386-393

  Tolleson, Thaddeus R ^a   Conor O'Shea, J ^a   Bittl, John A ^b   Hillegass, William B ^c   Williams, Kathryn A ^a   Levine, Glenn ^d   Harrington, Robert A ^a   Tcheng, James E ^a,e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Ocala Heart and Vascular Institute   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TICLOPIDINE; TIROFIBAN;

ADULT; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART MUSCLE REVASCULARIZATION; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TREATMENT OUTCOME;

EID: 0037419770     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02767-5     Document Type: Article

References (19)

1. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-5.
2. McGarry TF Jr., Gottlieb RS, Morganroth J, et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992;123:1445-51.
3. Narins CR, Hillegass WB Jr., Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-71.
4. Frierson JH, Dimas AP, Simpfendorfer CC, Pearce G, Miller M, Franco I. Is aggressive heparinization necessary for elective PTCA? Cathet Cardiovasc Diagn 1993;28:279-82.
5. Chew DP, Bhatt DL, Lincoff MA, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961-6.
6. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-44.
7. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptolkinase. J Am Coll Cardiol 1988;11:1-11.
8. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-13.
9. Stone CJ, Koo CY. Additive splines in statistics In: Proceedings of the Statistical Computing Section. Alexandria, VA: American Statistical Association, 1985:45-8.
10. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II (IMPACT-II). Lancet 1997;349:1422-8.
11. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674-84.
12. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
13. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
14. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: the Randomised Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) investigation. Circulation 1997;96: 1445-53.
15. Lincoff MA, Tcheng JE, Califf RM, et al., the PROLOG Investigators. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 1997;79:286-91.
16. Leon MB, Baim DS, Popma JJ, et al., the Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339:1665-71.
17. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
18. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full ANTicoagulation versus ASpirin and TIClopidine (FANTASTIC) study. Circulation 1998;98:1597-603.
19. Bittl JA, Ahmed WH. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasrtry. Am J Cardiol 1998;82:50-6P.